The Biotech Growth Trust PLC Announces Market Purchase of Its Own Shares

Strategic Insights -

The Biotech Growth Trust PLC has initiated a market purchase program to buy back its own shares up to an aggregate maximum of 4,255,299. As part of this program, the company has purchased a total of 151,422 ordinary shares of 25p each for cancellation. This transaction brings the total number of ordinary shares in issue to 25,915,422, which will be used by shareholders to determine their interest in the company under the FCA's Disclosure Guidance and Transparency Rules.

Key Takeaways:

  • The Biotech Growth Trust PLC has been authorized to make market purchases of its own shares up to an aggregate maximum of 4,255,299.
  • The company has purchased a total of 151,422 ordinary shares of 25p each for cancellation at a price of 721.89 pence per share.
  • The total number of ordinary shares that the company has in issue is 25,915,422.
  • The figure of 25,915,422 will be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the company under the FCA's Disclosure Guidance and Transparency Rules.
  • Katherine Manson, Company Secretary, Frostrow Capital LLP, has made the announcement on behalf of the company.
  • The company does not currently hold any ordinary shares in treasury.
  • The purchase was made under the authority granted at the General Meeting of the Company held on 27 February 2025.

Statistics:

  • 151,422 ordinary shares of 25p each were purchased for cancellation at a price of 721.89 pence per share.
  • The total number of ordinary shares that the company has in issue is 25,915,422.
  • The aggregate maximum number of shares that the company is permitted to purchase under the market purchase program is 4,255,299.
  • The purchase price of 721.89 pence per share was used to acquire the ordinary shares.
  • The company's ordinary shares have a par value of 25p each.

Sources:

  • PR Newswire For immediate release June 27, 2025
  • The Biotech Growth Trust PLC
  • Frostrow Capital LLP
  • FCA's Disclosure Guidance and Transparency Rules